Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Abaloparatide→

Abaloparatide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
247062-33-5
Molecular formula
C174H300N56O49
Molecular weight
3961 g/mol
Drug class
Parathyroid Hormone-Related Peptide Analog
Mechanism of action
Parathormone Receptor Agonists
Indications / reported uses
  • Osteoporosis, Postmenopausal
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Abaloparatide Environmental Risk Assessment (ERA) (the Abaloparatide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.